68 results
8-K
EX-99.2
BLUE
Bluebird bio Inc
8 Jan 24
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8:03am
.
Closing 20
CONFIDENTIAL Established gene therapy leader poised to deliver shareholder value 21 Established Clinical Leadership 10+ years of gene
424B5
BLUE
Bluebird bio Inc
20 Dec 23
Prospectus supplement for primary offering
5:05pm
gene addition platform. In 2022, following more than a decade of leadership in research and clinical development, we received approval from the U.S. Food … vector (“LVV”) gene addition platform. In 2022, following more than a decade of leadership in research and clinical development, we received approval
424B5
BLUE
Bluebird bio Inc
18 Dec 23
Prospectus supplement for primary offering
5:07pm
vector gene addition platform. In 2022, following more than a decade of leadership in research and clinical development, we received approval from … , following more than a decade of leadership in research and clinical development, we received approval from the U.S. Food and Drug Administration (the “FDA
8-K
EX-99.1
BLUE
Bluebird bio Inc
11 Dec 23
Regulation FD Disclosure
8:06am
shareholder value Established Clinical Leadership 10+ years of gene therapy research 180+ patients treated 8 clinical trials Experienced team 100
424B5
7igphd8j
8 Aug 23
Prospectus supplement for primary offering
9:03am
8-K
EX-99.1
7ocj9rrsvxi2
12 Jul 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
k8yhfel3pa
12 Jun 23
Regulation FD Disclosure
7:28am
S-3
j91p7llg1dxf81wgz
9 May 23
Shelf registration
4:28pm
PRE 14A
nznpr
18 Apr 23
Preliminary proxy
5:09pm
8-K
EX-99.1
3acgo
8 Oct 21
Other Events
5:03pm
8-K
q8tomhr1fejvxig
5 Oct 21
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
35pzzmmazit
7 Sep 21
Gina Consylman appointed chief financial officer, severe genetic disease
4:09pm
8-K
EX-99.1
ttlz9ooxlz7o2 0a
9 Aug 21
Results of Operations and Financial Condition
7:02am